Cipher Pharmaceuticals Inc. announced that it has entered into an exclusive distribution and supply agreement with Italmex Pharma S.A. under which Cipher has granted Italmex exclusive rights to market, sell and distribute Cipher's Isotretinoin product in Mexico. Under the terms of the agreement with Italmex, Cipher will receive an upfront payment and is eligible for additional regulatory and commercial milestone payments. Cipher will supply the product to Italmex and product manufacturing will be done by Cipher's partner, Galephar Pharmaceutical Research. Italmex will be responsible for all regulatory activities associated with gaining and maintaining regulatory approval of the product in Mexico.